Description
[ CAS NO. ] 14605-22-2
[ Molecular Formula ] C26H45NO6S
[ Molecular weight ] 499.707
[ Appearance ] White powder
Application of Tauroursodeoxycholic acid (TUDCA)
TUDCA has significant protective properties for many organs throughout the human body.It protects skeletal muscles and other organs, particularly the liver, by increasing insulin sensitivity to appropriate levels.TUDCA has shown to do this by protecting endoplasm reticulum from stress.
Insulin resistance plays a large part in health issues related to excess fat.TUDCA is used for many liver healing and immune-improving purposes, and also is used to support a healthy gallbladder.
This dietary supplement may have some powerful neuroprotective properties, and is indicated in the protection of cells from destruction.To protect cells, TUDCA modulates certain cell cycle effector genes.While these signaling pathways have been identified, the full role of TUDCA in cell maintenance is not yet fully understood.
By protecting cells from destruction, TUDCA has proven to be effective in helping eye’s maintain cones and rods.This photoreceptor protection can go a long way in promoting healthy vision. TUDCA is also linked to increased antioxidant activity.
COA of Tauroursodeoxycholic Acid
Rotation: +46.0°
Melting Point: 201.9-202.4℃
Maximum impurity（%）: 0.1%
Residue on ignition（%）: 0.02%
Chloride（%）: 0.016%
Loss on drying: 0.15%
Heavy Metals（PPM）: 1.0
Pb: ≤2ppm
As: ≤2ppm
Hg: ≤1ppm
Total plate count: ≤1000CFU/g
Yeast&mold: ≤100CFU/g
E.coli: Negative
Salmonella: Negative
Assay: 99.45%
About Tauroursodeoxycholic Acid (TUDCA)
Tauroursodeoxycholic acid (TUDCA) is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid (UDCA). Humans are found to have trace amounts of TUDCA. However, bears contain large amounts of TUDCA in their bile; UDCA and conjugates comprise about 47% of the bile in American black bears and up to 76% in Asiatic bears.
TUDCA has been used in ancient Asian pharmacopoeias for its supposed beneficial effects. UDCA is produced in several countries for the treatment of gallstones and liver cirrhosis. It is not approved by the Food and Drug Administration, in the U.S. while UDCA is approved in the United States for the treatment of primary biliary cirrhosis Ongoing research is finding TUDCA has diminishing apoptotic effects, with potential application in cardiac disease, Huntington’s disease, Parkinson’s disease, and stroke. Recently, TUDCA has been found to have protective effects in the eye, especially concerning retinal degenerative disorders.
